title: Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies.
abstract: To determine the protective potential of the humoral immune response against HIV-1 in vivo we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in suppressing viral rebound in six acutely and eight chronically HIV-1-infected individuals undergoing interruption of antiretroviral treatment (ART). Only two of eight chronically infected individuals showed evidence of a delay in viral rebound during the passive immunization. Rebound in antibody-treated acutely infected individuals upon cessation of ART was substantially later than in a control group of 12 individuals with acute infection. Escape mutant analysis showed that the activity of 2G12 was crucial for the in vivo effect of the neutralizing antibody cocktail. By providing further direct evidence of the potency, breadth and titers of neutralizing antibodies that are required for in vivo activity, these data underline both the potential and the limits of humoral immunity in controlling HIV-1 infection.
authors.affiliation: Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland. alexandra.trkola@usz.ch
authors.forename: Alexandra
authors.initials: A
authors.lastname: Trkola
authors.forename: Herbert
authors.initials: H
authors.lastname: Kuster
authors.forename: Peter
authors.initials: P
authors.lastname: Rusert
authors.forename: Beda
authors.initials: B
authors.lastname: Joos
authors.forename: Marek
authors.initials: M
authors.lastname: Fischer
authors.forename: Christine
authors.initials: C
authors.lastname: Leemann
authors.forename: Amapola
authors.initials: A
authors.lastname: Manrique
authors.forename: Michael
authors.initials: M
authors.lastname: Huber
authors.forename: Manuela
authors.initials: M
authors.lastname: Rehr
authors.forename: Annette
authors.initials: A
authors.lastname: Oxenius
authors.forename: Rainer
authors.initials: R
authors.lastname: Weber
authors.forename: Gabriela
authors.initials: G
authors.lastname: Stiegler
authors.forename: Brigitta
authors.initials: B
authors.lastname: Vcelar
authors.forename: Hermann
authors.initials: H
authors.lastname: Katinger
authors.forename: Leonardo
authors.initials: L
authors.lastname: Aceto
authors.forename: Huldrych F
authors.initials: HF
authors.lastname: Günthard
mesh_terms: D000208:Acute Disease; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002908:Chronic Disease; D005260:Female; D015483:HIV Antibodies / Q000627:therapeutic use*; D015658:HIV Infections / Q000628:therapy*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007116:Immunization, Passive; D008297:Male; D008875:Middle Aged; D009154:Mutation; D019562:Viral Load; D014779:Virus Replication
chemical_list: D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D015483:HIV Antibodies